Dr. Philipp Scherer talks about the future possibility of an “exercise pill” or something that would increase metabolism, repress appetite, and simulate the effects of exercise so that patients could maintain a normal weight without diet or exercise. He expects that clinical trials might happen in the next 5-7 years but it may take a while before we actually see an FDA-approved medication for such a medication.
More videos with Dr. Scherer:
Philipp Scherer, Ph.D., Professor, UT Southwestern, Introduction
Q1: Role of Adipose Tissue in Metabolic Health
Q2: Is there such a thing as “healthy” obesity?
Q3: Effects of Lipotoxicity on Beta Cells
Q4: How does lipotoxicity relate to type 2 diabetes?
Q5: How does lipotoxicity affect CV disease in type 2 diabetes?
Q6: What is the role of mitochondria in brown fat?
Q7: Difference between “healthy” obese and non-healthy obese
Q8: Genetics of Metabolically Healthy Obese Individuals
Q9: Potential pharmacological innovations in metabolism control
Dr. Philipp Scherer is Professor and Director of the Touchstone Diabetes Center at the University of Texas Southwestern Medical Center in Dallas. Dr. Scherer received his Ph.D. degree from the University of Basel, Switzerland working on mitochondrial biogenesis, followed by post-doctoral time in the Whitehead Institute at the Massachusetts Institute of Technology. In 1997, he joined the faculty of the Albert Einstein College of Medicine where he was a Professor for Cell Biology and Medicine until his move to Dallas in early 2007. Current efforts in his laboratory are focused on the identification and physiological characterization of novel proteins that serve as potential links between the adipocyte and the processes of whole body energy homeostasis, inflammation and cancer.